An unexpected way to cause leukemia

Leukaemia – cancer of blood or bone marrow – is caused by mutations that allow defective blood cells to accumulate and displace healthy blood. To devise effective therapies it is crucial to know which mutations cause leukaemia and which cell type gives rise to leukaemic cells.

Researchers from the European Molecular Biology Laboratory (EMBL) in Italy, the EMBL-European Bioinformatics Institute, UK, and the Universities of Harvard, USA, and Lund, Sweden, have now used genetic engineering to introduce a mutation found in human leukaemia patients into mice. In the current issue of Cancer Cell they report that the mutation causes leukaemia by triggering innate genetic programmes that allow white blood cells to proliferate uncontrollably. The findings have implications for the way leukaemia should be treated.

Blood is generated from a small number of multipotent stem cells that divide, differentiate and give rise to the many different cell types that make up the blood. At the same time they also maintain the pool of stem cells through a process called self-renewal. While differentiating, cells acquire specific properties and functions, but lose the capacity to self-renew in the way stem cells do. Mutations interfering with this process and promoting uncontrolled proliferation of certain blood cells can lead to leukaemia. Researchers of the group of Claus Nerlov at EMBL’s Mouse Biology Unit now prove that a mutation in a protein called C/EBPa causes acute myeloid leukaemia (AML), a type of leukaemia affecting one lineage of white blood cells, in mice.

“10 percent of all patients suffering from AML have this mutation, but we could never be sure if it causes the disease. By precisely reproducing the human mutation in the mouse we now proved a causative relation,” says Peggy Kirstetter, who carried out the research in Nerlov’s lab.

Instead of promoting uncontrolled proliferation of malignant blood stem cells, as often assumed as the cause of leukaemia, the mutation acts on already partially differentiated cells. It reprogrammes these cells to self-renew and to produce countless dysfunctional daughter cells, which displace the healthy blood cells, eventually leading to the inability to transport oxygen around in the body.

“This is the first time that non-stem cell myeloid leukaemia has been generated within a healthy blood system. The findings will have profound implications for our understanding of the development and treatment of leukaemias,” says Nerlov.

Scientists always thought that the mutation was the crucial step leading to leukaemia that should be targeted by drugs. Nerlov and colleagues identified a genetic programme activated in self-renewing leukemic cells, which is shared with similar leukaemias caused by other types of mutations. The findings suggest that the cellular changes that lead to self-renewal are mutation-independent. To develop drugs with a more general efficacy it may therefore be more efficient to target the molecules and pathways shared between different cancer stem cells.

Source: European Molecular Biology Laboratory

Related stories:

Increased cancer risk following the use of radioactive Radium-224 in the therapy
Ankylosing Spondylitis (Bechterew's Disease) is a painful chronic inflammatory rheumatic disease, associated with stiffening of the vertrebral column. Between 100,000 and 150,000 cases have already been diagnosed in Germany, but milder forms of the disease may remain undiagnosed.
Connecting cancer genes
A large genetic study in mice has identified hundreds of genes involved in the development of cancer by examining the DNA of more than 500 lymphomas to find the cancer causing mutations.
Are dual cord blood banks the answer to increasing stem cell demand?
Demand for stem cells from cord blood is greater than supply. In this week’s BMJ, two senior doctors, Professors Nicholas Fisk and Rifat Atun, analyse the UK’s growing cord blood banking industry and the potential impact of a new bank that provides blood for both personal and public use.
Discovery major step forward in treating leukemia
Researchers at the University of East Anglia have discovered for the first time a pathway that makes cancerous leukaemia cells resistant to treatment.
T vs. B: Re-engineered human T cells effectively target and kill cancerous B cells
Human white blood cells, engineered to recognize other malignant immune cells, could provide a novel therapy for patients with highly lethal B cell cancers such as acute lymphoblastic leukemia (ALL), according to researchers at Memorial Sloan-Kettering Cancer Center (MSKCC). By administering repeated doses of T cells designed to express an artificial receptor which recognizes human B cells, the researchers were able to eradicate cancer in 44 percent of mice bearing human ALL tumors.
New research provides hope for childhood cancer sufferers
Dr Richard Lock, Head of the Leukaemia Biology Program at the Children’s Cancer Institute Australia for Medical Research, Sydney, along with collaborators from the Childrens Hospital Los Angeles and University of Southern California, USA, recently published their findings in the prestigious scientific journal Blood.
New research provides hope for childhood cancer sufferers
Scientists investigating drug therapies for children with Acute Lymphoblastic Leukaemia (ALL) have presented new data demonstrating for the very first time that a small molecule called ABT-737 can increase the effectiveness of standard therapies.
DNA damage to stem cells is central to ageing
DNA damage is a major mechanism behind the loss of adult stem cells over time, according to a Nature paper by Oxford University researchers and international colleagues.

News discussion:

Medicine & Health news